|
1. Sarafidis, P.A., Li S, Chen S.C., Collins A.J., Brown W.W., Klag M.J., et al.,Hypertension awareness, treatment, and control in chronic kidney disease. Am JMed, 2008. 121(4): p. 332-40. 2. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension, 2003. 41(6): p. 1341-5. 3. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., et al., Blood pressure and end-stage renal disease in men. N Engl J Med, 1996.334(1): p. 13-8. 4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002. 39(2 Suppl 1): p. S1-266. 5. Lackland, D.T., Hypertension: Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure guidelines. Curr Opin Neurol, 2013. 26(1): p. 8-12. 6. Hermida R.C., Ayala D.E., Moj?曝 A, Fern?鴨dez J.R., Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol, 2011. 22(12): p. 2313-21. 7. Agarwal, R. and M.J. Andersen, Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int, 2006. 69(7): p. 1175-80. 8. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2007. 28(12): p. 1462-536. 9. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al., Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension, 2005. 46(1): p. 156-61. 10. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, et al., Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension, 2005. 45(2): p. 240-5. 11. Staessen J.A., Thijs L, Fagard R, O'Brien E.T., Clement D, de Leeuw P.W., et al., Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA, 1999. 282(6): p. 539-46. 12. Hermida R.C., Ayala D.E., Moj?曝 A, Fern?鴨dez J.R., Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int, 2010. 27(8): p. 1629-51. 13. Minutolo R, Gabbai F.B., Borrelli S, Scigliano R, Trucillo P, Baldanza D, et al., Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis, 2007. 50(6): p.908-17. 14. Hermida R.C., Ayala D.E., Fern?鴨dez J.R., Calvo C., Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension, 2008. 51(1): p. 69-76. 15. Hermida R.C., Calvo C, Ayala D.E., L?櫝ez J.E., Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension, 2005. 46(4): p. 960-8. 16. Neuringer, J.R. and Brenner B.M., Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Dis, 1993. 22(1): p. 98-104. 17. Bidani, A.K. and Griffin K.A., Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens, 2002. 11(1): p.73-80. 18. Bidani, A.K., Schwartz M.M., and Lewis E.J., Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol, 1987. 252(6 Pt 2): p. F1003-10. 19. Bakr is G.L., Williams M, Dworkin L, Elliott W.J., Epstein M, Toto R, et al., Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis, 2000. 36(3): p. 646-61. 20. Langham R.G., Kelly D.J., Cox A.J., Thomson N.M., Holth?仜er H, Zaoui P, et al., Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia, 2002. 45(11): p. 1572-6. 21. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T, Pohl M.A., Lewis J.B., et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001. 345(12): p. 851-60. 22. Brenner B.M., Cooper M.E., de Zeeuw D, Keane W.F., Mitch W.E., Parving H.H., et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001. 345(12): p. 861-9.23. Wright J.T. Jr, Bakris G, Greene T, Agodoa L.Y., Appel L.J., Charleston J, et al., Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002. 288(19): p. 2421-31. 24. Lazarus J.M., Bourgoignie J.J., Buckalew V.M., Greene T, Levey A.S., Milas N.C., et al., Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension, 1997. 29(2): p. 641-50. 25. Agarwal, R. and Sinha A.D., Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension, 2009. 53(5): p. 860-6. 26. Mourad J.J., Pannier B, Blacher J, Rudnichi A, Benetos A, London G.M., et al., Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int, 2001. 59(5): p. 1834-41.
|